Appendix B: Sources of evidence considered by the Committee
A. The Evidence Review Group (ERG) report for this appraisal was prepared by the School of Health and Related Research, University of Sheffield:
-
Holmes M, Caroll C, Papaioannou D, Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: A Single Technology Appraisal, May 2008.
B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on dabigatran by providing a written statement to the Committee. Organisations listed in I and II have the opportunity to appeal against the final appraisal determination.
I) Manufacturer/sponsor:
-
Boehringer Ingelheim (dabigatran)
II) Professional/specialist and patient/carer groups:
-
Anticoagulation Europe
-
British Association for Surgery of the Knee
-
British Haematology Society
-
British Orthopaedic Association
-
British Society for Haemostasis and Thrombosis
-
British Thoracic Society
-
DVT Awareness Campaign
-
Lifeblood: The Thrombosis Charity
-
Royal College of Nursing
-
Royal College of Pathologists
-
Royal College of Physicians
III) Other consultees
-
Department of Health
-
Welsh Assembly Government
IV) Commentator organisations (did not provide written evidence and without the right of appeal)
-
Department of Health, Social Services and Public Safety for Northern Ireland
-
GlaxoSmithKline (fondaparinux sodium)
-
National Collaborating Centre for Acute Care
-
National Coordinating Centre for Health Technology Assessment
-
NHS Quality Improvement Scotland
-
Pfizer (dalteparin sodium)
-
sanofi-aventis (enoxaparin sodium)
-
School of Health & Related Research Sheffield (ScHARR)
C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on dabigatran by providing oral evidence to the Committee.
-
Professor Roger Atkins, consultant orthopaedic surgeon, nominated by the British Orthopaedic Association – clinical specialist
-
Mrs Diane Eaton, nominated by Anticoagulation Europe (ACE) – patient expert